The purpose of this study is to establish a safe dose of study cells (ATLCAR.CD30.CCR4 and ATLCAR.CD30) to give to patients with CD30+ refractory/relapsed Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma.

Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.

Have you been diagnosed with melanoma? If so, you may be eligible to take part in a research study looking at the safety of giving a combination of drugs called Ulixertinib and Palbociclib to patients with advanced melanoma.

The purpose of this study is to establish a safe dose of study cells to give to patients with relapsed/ refractory ALL expressing CD19.

Do you have bladder, kidney, prostate, or another genitourinary cancer diagnosis? If so, you may be able to take part in a research study collecting specimens (e.g., blood, urine, saliva, tissue) during your already scheduled appointments. Collecting these specimens may help researchers develop new ways to detect cancer earlier or to more effectively treat cancer.

The goal of this study is to help CAPRICORN understand the needs of primary care clinics in North Carolina that provide free or low-cost healthcare. We will focus on how these clinics can offer cancer screening events to people in the community. To do this, we will create and use a survey to learn more about the needs of 3-4 clinics in North Carolina. Our findings will be shared in a report that includes suggestions for how CAPRICORN can grow over the next five years.

To evaluate whether different biomarkers can stratify patients with newly diagnosed GBM that have progressive enhancement within 12 weeks post-XRT into risk groups based on overall survival.

The overall objective of this project is to examine differences in performance fatigability and contributing mechanisms between firefighters in cancer remission and healthy firefighter controls. Findings from this research project will inform future interventions to reduce CRF in firefighters in cancer remission.

The purpose of this study is to measure the effect of 30 mg RE104 on adjustment disorder symptoms (depressed mood or anxiety) compared to 1.5 mg RE104 in participants with cancer or other illnesses in order to decrease these symptoms.

To evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization procedures, procedures to stop blood flow to certain tumors.